EE512 Potential Long-Term Benefits of Extended Adjuvant Neratinib in Patients with High-Risk Hormone Receptor Positive (HR+) HER2+ Early-Stage Breast Cancer (ESBC) Following Use of T-DM1 or Pertuzumab: A Population Effectiveness Model
Veenstra, D., Oestreicher, N., Dolan, C.M., Fisher, K.A., Pandey, R., Elsea, D., Brufsky, A.
Published in Value in health (01.06.2023)
Published in Value in health (01.06.2023)
Get full text
Journal Article
EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective
Liu, T, Purser, M, Gong, C, Elsea, D, Niehoff, N, Dlotko, E, Migliaccio-Walle, K., Samyshkin, Y
Published in Value in health (01.06.2024)
Published in Value in health (01.06.2024)
Get full text
Journal Article
Chinese "architectural village" remakes masterpieces
Get full text
Magazine Article
Trade Publication Article